Volume 127, Issue 3

Search all Breast Cancer Research and Treatment articles

June 2011

Filter by

Volume:

Sort by

Date published:

New to old Old to new

32 articles in this issue

MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups
Mohammed A. Aleskandarany
Emad A. Rakha
Andrew R. Green
Preclinical study 11 July 2010 Pages: 591 - 599
Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer
Maurizio Callari
Vera Cappelletti
Maria Grazia Daidone
Preclinical study 13 July 2010 Pages: 601 - 610
Ionizing radiation or mitomycin-induced micronuclei in lymphocytes of BRCA1 or BRCA2 mutation carriers
Sara Gutiérrez-Enríquez
Teresa Ramón y Cajal
Orland Diez
Preclinical study 13 July 2010 Pages: 611 - 622
Elevated TRF2 in advanced breast cancers with short telomeres
Malissa C. Diehl
Michael O. Idowu
Lynne W. Elmore
Preclinical study 13 July 2010 Pages: 623 - 630
Native MAG-1 antibody almost destroys human breast cancer xenografts
William G. North
Roy H. L. Pang
Bernard F. Cole
Preclinical study 13 July 2010 Pages: 631 - 637
Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation
Julie Richardson
Abeer M. Shaaban
Sandra M. Bell
Preclinical study 15 July 2010 Pages: 639 - 648
Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo
Sumito Sato
Charlotte Kopitz
Viktor Magdolen
Preclinical study 16 July 2010 Pages: 649 - 657
GRB7 protein over-expression and clinical outcome in breast cancer
Betsy Ramsey
Tao Bai
Shiuh-Wen Luoh
Preclinical study 16 July 2010 Pages: 659 - 669
International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation
Ana Peixoto
Catarina Santos
Manuel R. Teixeira
Preclinical study 22 July 2010 Pages: 671 - 679
Women’s interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid
Angela Fagerlin
Amanda J. Dillard
Peter A. Ubel
Clinical trial 26 March 2011 Pages: 681 - 688
A phase I clinical and pharmacological study evaluating vinflunine in combination with doxorubicin as first line treatment in metastatic breast cancer
K. Zaman
X. Durando
J. Bauer
Clinical trial 26 March 2011 Pages: 689 - 696
Change in blood flow velocity demonstrated by Doppler ultrasound in upper limb after axillary dissection surgery for the treatment of breast cancer
Carolina Nascimben Matheus
Elaine Caldeira de Oliveira Guirro
Clinical trial 29 March 2011 Pages: 697 - 704
A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?
Meijun Long
Weijuan Jia
Erwei Song
Clinical Trial 29 March 2011 Pages: 705 - 712
Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes
G. Cancello
P. Maisonneuve
M. Colleoni
Clinical trial 31 March 2011 Pages: 713 - 720
Socioeconomic differences in survival among breast cancer patients in the Netherlands not explained by tumor size
E. Bastiaannet
A. J. M. de Craen
G. J. Liefers
Epidemiology 13 November 2010 Pages: 721 - 727
Disparities in breast cancer characteristics and outcomes by race/ethnicity
Siew Loon Ooi
Maria Elena Martinez
Christopher I. Li
Epidemiology 07 October 2010 Pages: 729 - 738
Economic evaluation of the 21-gene signature (Oncotype DX^®) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03)
Masahide Kondo
Shu-Ling Hoshi
Masakazu Toi
Epidemiology 17 November 2010 Pages: 739 - 749
CAG repeat length polymorphism in the androgen receptor gene and breast cancer risk: data on Indian women and survey from the world
Singh Rajender
Amirtharaj Francis
Kumarasamy Thangaraj
Epidemiology 24 November 2010 Pages: 751 - 760
Variation in genes coding for AMP-activated protein kinase (AMPK) and breast cancer risk in the European Prospective Investigation on Cancer (EPIC)
Daniele Campa
Rainer Claus
Rudolf Kaaks
Epidemiology 30 November 2010 Pages: 761 - 767
A variant affecting miRNAs binding in the circadian gene Neuronal PAS domain protein 2 (NPAS2) is not associated with breast cancer risk
Furu Wang
Zhibin Hu
Hongbing Shen
Epidemiology 08 December 2010 Pages: 769 - 775
Joint effect of peroxisome proliferator-activated receptor γ genetic polymorphisms and estrogen-related risk factors on breast cancer risk: results from a case–control study in Taiwan
Mei-Hsuan Wu
Chi-Hong Chu
Chien-An Sun
Epidemiology 08 December 2010 Pages: 777 - 784
IGFBP1 and IGFBP3 polymorphisms predict circulating IGFBP-3 levels among women from high-risk breast cancer families
Ann H. Rosendahl
Maria Hietala
Helena Jernström
Epidemiology 08 December 2010 Pages: 785 - 794
Two functional variations in 5′-UTR of hoGG1 gene associated with the risk of breast cancer in Chinese
Xiaoxiang Chen
Jingmei Wang
Yaping Wang
Epidemiology 14 December 2010 Pages: 795 - 803
Ability to predict breast cancer in Asian women using a polygenic susceptibility model
Mikael Hartman
Chen Suo
Kee Seng Chia
Epidemiology 14 December 2010 Pages: 805 - 812
Current evidence on the relationship between four polymorphisms in the matrix metalloproteinases (MMP) gene and breast cancer risk: a meta-analysis
Ping Zhou
Liang-Feng Du
Chun Zhang
Epidemiology 15 December 2010 Pages: 813 - 818
Risk of contralateral breast cancer associated with common variants in BRCA1 and BRCA2: potential modifying effect of BRCA1/BRCA2 mutation carrier status
Jane C. Figueiredo
Jennifer D. Brooks
Jonine L. Bernstein
Epidemiology 15 December 2010 Pages: 819 - 829
EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry
Anita L. Bane
Anna Marie Mulligan
Irene L. Andrulis
Brief Report 15 February 2011 Pages: 831 - 839
Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab
Mafalda Oliveira
Sofia Braga
João Oliveira
Brief Report 03 March 2011 Pages: 841 - 844
The h index and the identification of global benchmarks for breast cancer research output
N. A. Healy
R. W. Glynn
K. J. Sweeney
Brief Report 12 March 2011 Pages: 845 - 851
BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer
Michelle W. Wong
Cecilia Nordfors
Rodney J. Scott
Brief Report 16 March 2011 Pages: 853 - 859
PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy
Pawel Domagala
Tomasz Huzarski
Wenancjusz Domagala
Brief Report 17 March 2011 Pages: 861 - 869
Germline mutational analysis of the C19orf62 gene in African-American women with breast cancer
Yonglan Zheng
Jing Zhang
Dezheng Huo
Brief Report 24 March 2011 Pages: 871 - 877

Volume 127, Issue 3

MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups

Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer

Ionizing radiation or mitomycin-induced micronuclei in lymphocytes of BRCA1 or BRCA2 mutation carriers

Elevated TRF2 in advanced breast cancers with short telomeres

Native MAG-1 antibody almost destroys human breast cancer xenografts

Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation

Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo

GRB7 protein over-expression and clinical outcome in breast cancer

International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation

Women’s interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid

A phase I clinical and pharmacological study evaluating vinflunine in combination with doxorubicin as first line treatment in metastatic breast cancer

Change in blood flow velocity demonstrated by Doppler ultrasound in upper limb after axillary dissection surgery for the treatment of breast cancer

A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?

Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes

Socioeconomic differences in survival among breast cancer patients in the Netherlands not explained by tumor size

Disparities in breast cancer characteristics and outcomes by race/ethnicity

Economic evaluation of the 21-gene signature (Oncotype DX^®) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03)

CAG repeat length polymorphism in the androgen receptor gene and breast cancer risk: data on Indian women and survey from the world

Variation in genes coding for AMP-activated protein kinase (AMPK) and breast cancer risk in the European Prospective Investigation on Cancer (EPIC)

A variant affecting miRNAs binding in the circadian gene Neuronal PAS domain protein 2 (NPAS2) is not associated with breast cancer risk

Joint effect of peroxisome proliferator-activated receptor γ genetic polymorphisms and estrogen-related risk factors on breast cancer risk: results from a case–control study in Taiwan

IGFBP1 and IGFBP3 polymorphisms predict circulating IGFBP-3 levels among women from high-risk breast cancer families

Two functional variations in 5′-UTR of hoGG1 gene associated with the risk of breast cancer in Chinese

Ability to predict breast cancer in Asian women using a polygenic susceptibility model

Current evidence on the relationship between four polymorphisms in the matrix metalloproteinases (MMP) gene and breast cancer risk: a meta-analysis

Risk of contralateral breast cancer associated with common variants in BRCA1 and BRCA2: potential modifying effect of BRCA1/BRCA2 mutation carrier status

EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry

Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab

The h index and the identification of global benchmarks for breast cancer research output

BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer

PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy

Germline mutational analysis of the C19orf62 gene in African-American women with breast cancer

Navigation